KYBELLA® is the first and only FDA-approved injectable drug that contours and improves the appearance of submental fullness. KYBELLA® allows you to further expand your aesthetic injectable portfolio and offerings to your patients.
The number of injections and the number of treatments should be tailored to the individual patient’s submental fat distribution and treatment goals. Once the aesthetic response is achieved with KYBELLA®, retreatment is not expected.
KYBELLA® is supplied in a pack of 4 single patient use 2 mL vials. KYBELLA® is administered by subcutaneous injections into submental fat in approximately 0.2 mL per injection spaced 1 cm apart using a 30G or smaller needle.
Click here to print/download our Kybella® patient information:
Before & Afters
Results are represented over the course of treatment, not all treatments are shown. Up to 6 treatments may be administered, spaced no less than 1 month apart. In clinical trials, 59% of people treated with KYBELLA® received all 6 treatments.
Important Safety Information
KYBELLA® is contraindicated in the presence of infection at the injection sites.
Cases of marginal mandibular nerve injury, manifested as an asymmetric smile or facial muscle weakness, were reported in 4% of subjects in the clinical trials; all cases resolved spontaneously (range 1-298 days, median 44 days). KYBELLA® should not be injected into or in close proximity to the marginal mandibular branch of the facial nerve.
Dysphagia occurred in 2% of subjects in the clinical trials in the setting of administration site reactions, e.g., pain, swelling, and induration of the submental area; all cases of dysphagia resolved spontaneously (range 1-81 days, median 3 days). Avoid use of KYBELLA® in patients with current or prior history of dysphagia as treatment may exacerbate the condition.
In clinical trials, 72% of subjects treated with KYBELLA® experienced hematoma/bruising. KYBELLA® should be used with caution in patients with bleeding abnormalities or who are currently being treated with antiplatelet or anticoagulant therapy as excessive bleeding or bruising in the treatment area may occur.
To avoid the potential of tissue damage, KYBELLA® should not be injected into or in close proximity (1-1.5 cm) to salivary glands, lymph nodes and muscles.
The most commonly reported adverse reactions in the pivotal clinical trials were: injection site edema/swelling, hematoma/bruising, pain, numbness, erythema,and induration.